Smooth or Textured: A Lesson in Biocompatibility
The objective of the textured surface is to limit movement and reduce the formation of overly tight scar tissue. It is noteworthy here that the function of the textured surface depends on its ability to alter tissue response. Yet this can lead to inconsistent thinking in which positive effects of surface changes are touted while negative effects are denied. Unfortunately, textured surfaces on breast implants have also been linked to the development of Anaplastic Large Cell Lymphoma (ALCL), an adverse effect beyond any associated just with the long-term presence of silicone. FDA has noted that factors influencing ALCL inclu...
Source: MDDI - April 17, 2019 Category: Medical Devices Authors: William A. Hyman Tags: Materials Source Type: news

Spontaneous Remission in Diffuse Large Cell Lymphoma Spontaneous Remission in Diffuse Large Cell Lymphoma
An elderly patient with diffuse large B cell lymphoma achieved spontaneous remission after biopsy. What were the immunological and molecular variables that might have factored into tumor regression?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
Prevalence higher for advanced adenomas, advanced serrated lesions, serrated polyposis syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 15, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Journal, Source Type: news

Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
MONDAY, April 15, 2019 -- Hodgkin lymphoma (HL) survivors have an increased risk for advanced colorectal neoplasia, including advanced adenomas, advanced serrated lesions, and serrated polyposis syndrome, according to a study published in the March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 15, 2019 Category: Pharmaceuticals Source Type: news

‘If I had known cancer was linked to implants, I would never have gotten them’
Some women have been diagnosed with BIA-ALCL, a rare type of lymphoma. There have been 600 reported cases worldwide, with 17 deaths. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 13, 2019 Category: Consumer Health News Authors: Susan Berger Source Type: news

CD30: From witness to culprit
(Helmholtz Zentrum M ü nchen - German Research Center for Environmental Health) Cells of certain blood cancers such as Hodgkin's lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the risk of their occurrence, according to a report in the journal Blood by researchers of the Helmholtz Zentrum M ü nchen. A greatly increased number of CD30-bearing cells are produced after certain viral infections, e.g. Epstein-Barr virus (EBV) infection, and in autoimmune diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2019 Category: Cancer & Oncology Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Australia ’s TGA considering, but not yet implementing, textured breast implant ban
Australia’s TGA said yesterday that it is seeking new data from suppliers of textured breast implants, which have been linked to a rare immune-system cancer, before making a decision on whether or not to suspend or cancel those products from its Register of Therapeutic Goods. The regulatory body gave suppliers of the devices 10 working days to respond to the requests for more information, including dates they began to supply the devices and samples of the implants, according to a TGA release. The decision comes after the convening of a breast implant expert panel on April 8, following recent decisions made in Canada ...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cosmetic/Aesthetic Oncology Regulatory/Compliance Women's Health Source Type: news

PRIMA-PI Risk Score for Follicular Lymphoma Promising for Trials, Clinical Practice
Researchers compared the newly developed PRIMA-PI risk score against FLIPI and FLIPI-2 in patients with follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

New 'Cancer Vaccine' Attacks Tumors From Within
Eight out of 11 lymphoma patients in a small, early clinical trial had partial or complete destruction of the tumor that received the initial injection, according to the researchers’ report. (Source: WebMD Health)
Source: WebMD Health - April 9, 2019 Category: Consumer Health News Source Type: news

Let's Put Breast Implant Lymphoma Risk in Context Let's Put Breast Implant Lymphoma Risk in Context
Dr Kathy Miller discusses the importance of placing risks in context, and questions the level of side-effect risk required for fully informed consent.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

France Bans Textured Breast Implants
France has banned several types of textured breast implants that have been linked to a rare form of cancer, and more countries appear to be following suit, including Canada and the Netherlands. For years researchers have raised concern about the potential association between breast implants and anaplastic large cell lymphoma (ALCL), a very rare form of cancer, but France is the first country to ban the devices. The ban took effect on Friday and covers macro-textured implants and implants with a polyurethane coating. The National Agency for Safety of Medicines and Health Products (ANSM) in France notified manufa...
Source: MDDI - April 8, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Regulatory and Compliance Source Type: news

Health Canada notifies Allergan on intent to suspend Biocell breast implant license
Health Canada said yesterday that it plans to suspend Allergan‘s (NYSE: AGN) licenses to sell its Biocell breast implants in the region due to a possible association with a rare immune system-cancer. The move follows the agency’s completion of a scientific assessment of macro-textured implants, which it said is part of a larger safety review of breast implants and their association with breast implant-associated anapestic large cell lymphoma (BIA-ALCL), a type of non-Hodgkin’s lymphoma. Health Canada said it launched the review last November due to an increase in Canadian and international cases of B...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cosmetic/Aesthetic Regulatory/Compliance Women's Health Allergan Source Type: news

Report: France to ban textured breast implants
France is planning to ban textured breast implants, which have been linked a rare immune-system cancer, according to a report from France24. France’s National Agency for Medicines and Health Products began informing manufacturers on April 2 of its plans to ban manufacturing, distribution, importing, exporting, promotion and wearing of textured breast implants and polyurethane breast implants, according to the report. The soon-to-be-banned implants have been linked to breast implant-associated anapestic large cell lymphoma (BIA-ALCL), a type of non-Hodgkin’s lymphoma. France’s ANSM has been tracking indivi...
Source: Mass Device - April 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cosmetic/Aesthetic Featured Regulatory/Compliance Women's Health Source Type: news

France Is First to Ban Breast Implants Linked to Rare Cancer
The ban covers textured breast implants, which are suspected of being linked to anaplastic large-cell lymphoma. Regulators in other countries are following suit. (Source: NYT Health)
Source: NYT Health - April 5, 2019 Category: Consumer Health News Authors: CONSTANT MEHEUT Tags: Implants Breasts Plastic Surgery Accidents and Safety Allergan Inc France anaplastic large-cell lymphoma Source Type: news

ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Primary Radiotherapy Plays Important Role in Early Follicular Lymphoma
A retrospective study supported the role of primary radiotherapy in early-stage follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma
Umbralisib, an investigational oral inhibitor of PI3K-delta, has significant activity against relapsed/refractory marginal-zone lymphoma (MZL) and manageable side effects, according to early results from an ongoing phase 2b trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 4, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Umbralisib Offers Promise for Marginal Zone Lymphoma
Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Omega-3 fatty acid supplements, hypothyroidism could lower risk of T-zone lymphoma in dogs
(Morris Animal Foundation) Dogs that receive omega-3 fatty acid supplements or have hypothyroidism may be less likely to develop T-zone lymphoma (TZL). Those are two findings from Morris Animal Foundation-funded researchers at Colorado State University, who studied associations of environment and health history of the disease among golden retrievers. They published their results in the Journal of Veterinary Internal Medicine. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2019 Category: International Medicine & Public Health Source Type: news

Cancer survivor, 20, who was given days to live offers to refund the £3,000 put towards her funeral
Xsara Sanderson, 20, of Sc.horpe, was told she had stage 4 Hodgkin lymphoma last July after experiencing unexplained weight loss, and chest and neck pain. (Source: the Mail online | Health)
Source: the Mail online | Health - April 1, 2019 Category: Consumer Health News Source Type: news

Single agent umbralisib effective for relapsed slow-growing lymphoma
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma& Myeloma, at the AACR Annual Meeting 2019 in Atlanta. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Umbralisib shows early promise for patients with marginal zone lymphoma
(American Association for Cancer Research) The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Researchers discover how tumor-killing immune cells attack lymphomas in living mice
(Rockefeller University Press) In a study that will be published April 1 in the Journal of Experimental Medicine, researchers from the Institut Pasteur and INSERM reveal that chimeric antigen receptor (CAR) T cells can induce tumor regression by directly targeting and killing cancer cells, uncovering new details of how these immune cells work and how their effectiveness could be improved in the treatment of non-Hodgkin's lymphoma and other B cell cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Skin Care Guidelines for Patients With Mycosis Fungoides Skin Care Guidelines for Patients With Mycosis Fungoides
Optimal cleansers, moisturizers, and bathing habits are reviewed in these skin care guidelines for patients with cutaneous lymphoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

California Man Awarded $ 80 Million in Roundup Lawsuit
Jury previously found Roundup was a significant factor in plaintiff's non - Hodgkin lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Institutional, Source Type: news

Monsanto Ordered to Pay $80 Million in Roundup Cancer Case
The jury found that Monsanto should be held liable for the man ’ s cancer because it failed to warn him about the herbicide ’ s cancer risks. (Source: NYT Health)
Source: NYT Health - March 28, 2019 Category: Consumer Health News Authors: JULIA JACOBS Tags: Defoliants and Herbicides Hodgkin's Lymphoma Suits and Litigation (Civil) Bayer AG Monsanto Company Hardeman, Edwin California Hazardous and Toxic Substances Source Type: news

Bayer ordered to pay $81M in Roundup cancer case
A federal jury has ordered Bayer to pay $81 million to a California man who said his use of the company's Roundup weedkiller caused him to develop cancer. The ruling is the latest against Bayer involving Roundup, which was developed by St. Louis-based Monsanto before the company was acquired by Bayer last year for $62.5 billion. A San Francisco jury said Wednesday that the company is liable for the man's non-Hodgkin lymphoma, according to Reuters. Edwin Hardeman was awarded $5.9 million in compensatory… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Vince Brennan Source Type: news

Bayer ordered to pay $81M in Roundup cancer case
A federal jury has ordered Bayer to pay $81 million to a California man who said his use of the company's Roundup weedkiller caused him to develop cancer. The ruling is the latest against Bayer involving Roundup, which was developed by St. Louis-based Monsanto before the company was acquired by Bayer last year for $62.5 billion. A San Francisco jury said Wednesday that the company is liable for the man's non-Hodgkin lymphoma, according to Reuters. Edwin Hardeman was awarded $5.9 million in compensatory… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 27, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news

Jury rules Monsanto IS liable for man's cancer after his years using Roundup
Edwin Hardeman of Santa Rosa, California, has non-Hodgkin's lymphoma, a cancer of the immune system, after using Roundup to kill poison oak on his 56-acre property over 30 years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2019 Category: Consumer Health News Source Type: news

Heating up tumors could make CAR T therapy more effective, study finds
UCLAZhen GuFINDINGSA preclinical study led by scientists at theUCLA Jonsson Comprehensive Cancer Center suggests that heating solid tumors during CAR T-cell therapy can enhance the treatment ’s success.The researchers found that when a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumor growth for up to 20 days in mice. Among the mice that were treated with the combination, 33 percent were still tumor free after the 20-day mark.BACKGROUNDT cells that have been genetically engineered with chimeric antigen receptor, or CAR, have successfully been us...
Source: UCLA Newsroom: Health Sciences - March 27, 2019 Category: Universities & Medical Training Source Type: news

More Info on Risks of Breast Implants Needed, Says FDA Panel More Info on Risks of Breast Implants Needed, Says FDA Panel
A 2-day meeting highlighted the risk for a rare lymphoma, described as a'man-made cancer,'and heard calls for a ban on certain products, but advisers also highlighted lack of data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 27, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bellwether Glyphosate Cancer Trial Heads To Phase 2 To Determine Liability
SAN FRANCISCO - Phase 2 of the federal bellwether glyphosate cancer trial in California started March 20, after a jury the first phase found that the chemical, which is the active ingredient in Monsanto Co.'s herbicide Roundup, was "a substantial factor" in causing the plaintiff's non-Hodgkin lymphoma (NHL) (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

Glyphosate A 'Substantial Factor' In Causing Cancer, Jury Says; Trial Continues
SAN FRANCISCO - A jury in a federal bellwether glyphosate cancer trial in California on March 19 found that the chemical, which is the active ingredient in Monsanto Co.'s herbicide Roundup, was "a substantial factor" in causing the plaintiff's non-Hodgkin lymphoma. Phase 2 of the trial, to determine liability and damages, is slated to begin March 20 (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

Study: People Exposed To Glyphosate Have Increased Risk Of Cancer
LONDON - A study published in the International Journal of Epidemiology on March 18 found that there was an elevation of risk for non-Hodgkin lymphoma (NHL) in people who were exposed to glyphosate, the active ingredient in the herbicide Roundup. (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - March 26, 2019 Category: Medical Law Source Type: news

FDA Scrambles to Prevent Shortages Amid Sterilization Shutdowns
Shutdowns of two facilities that use ethylene oxide to sterilize medical devices have raised concern about potential shortages in the medtech industry because this is such a popular sterilization method for medical devices. Ethylene oxide (EtO) is a flammable, colorless gas used to make a range of products. EtO also is used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. According to the EPA, long-term exposure to EtO can irritate the eyes,...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

FDA Panel: Too early to pull textured breast implants over cancer risk, need more data
A panel of experts convened by the FDA yesterday said that there’s not enough data to pull textured breast implants from the market over concerns that they may be linked to a type of immune system cancer, according to an AP News report. The recommendation comes from the first day of a two-day panel meeting discussing the risks associated with breast implant devices, reviewing current study data and exploring how to best track and treat the cancer, and other issues, the devices have been tied to. The FDA only began reporting on the cancer, known as breast implant-associated anaplastic large cell lymphoma, and its link...
Source: Mass Device - March 26, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Oncology Women's Health Source Type: news

Are Breast Implants Safe Enough? FDA Review Happening This Week
(CNN) — Many women have breast implants with no serious complications, but there have been cases where women suffer pain and fatigue, among other health problems. Now, the US Food and Drug Administration plans to hold a meeting to take a closer look at such cases and put breast implant safety under a microscope. The FDA will convene a meeting of the Medical Devices Advisory Committee’s General and Plastic Surgery Devices Panel on Monday and Tuesday to discuss and make recommendations relating to the risks and benefits of breast implants. The meeting, which will be open to the public, comes just days after the F...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 25, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Source Type: news

J&J and Sientra get FDA warning letters over breast implants
U.S. Food and Drug Administration takes another look at breast implants because of renewed safety concerns over a type of lymphoma. (Source: CBC | Health)
Source: CBC | Health - March 22, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

ER Doc Survives Cancer, Now Must Survive ER ER Doc Survives Cancer, Now Must Survive ER
A Florida-based ER physician with an aggressive lymphoma underwent a'miracle'treatment but now has a weakened immune system. Back at work, now he has to survive the ER and its germs.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 22, 2019 Category: Internal Medicine Tags: Hematology-Oncology News Source Type: news

Watch where you spray: Study reveals high pesticide exposure is linked to olfactory impairment in aging farmers
(Natural News) Some of the dangers of pesticide exposure are painfully obvious – just ask the many people suffering from non-Hodgkin lymphoma after years of exposure to glyphosate. However, some negative effects are far more insidious, sneaking up on people so slowly that they don’t even make the connection to pesticide exposure. Case in point:... (Source: NaturalNews.com)
Source: NaturalNews.com - March 22, 2019 Category: Consumer Health News Source Type: news

City of Hope awarded $7.5 million to develop better treatment for a rare, incurable cancer
(City of Hope) City of Hope recently received $7.5 million to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma. The NCI awarded $6.3 million over five years to City of Hope's Steven Rosen, M.D., and Christiane Querfeld, M.D., Ph.D., so they can develop improved therapies for the disfiguring, incurable cancer that affects about 3,000 new individuals per year. LLS gave the pair two grants totaling $1.2 million over three years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2019 Category: International Medicine & Public Health Source Type: news

Study gives new perspective on production of blood cells and immune cells
(University of California - Santa Cruz) A new study provides a thorough accounting of blood cell production from hematopoietic stem cells. The results are important for understanding disorders such as anemia, diseases of the immune system, and blood cancers such as leukemias and lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

Study: Antiretroviral therapy crucial in preventing non-Hodgkin lymphoma
A new study out of the Yale School of Public Health underscores the importance of T-cell count and viral load in developing cancer among those with HIV/AIDS. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 20, 2019 Category: Universities & Medical Training Source Type: news

Jury finds Monsanto's Roundup weed killer contributed to man's cancer
For the second time, a jury has found Monsanto's Roundup weed killer played a role in causing cancer. Tuesday's unanimous decision determined Roundup caused or was a "substantial factor" in causing 70-year-old Edwin Hardeman's non-Hodgkin's lymphoma. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

Monsanto Weedkiller Roundup Was ‘ Substantial Factor ’ in Causing Man ’ s Cancer, Jury Says
The finding was the first verdict from a federal jury in thousands of similar cases against the company. (Source: NYT Health)
Source: NYT Health - March 20, 2019 Category: Consumer Health News Authors: MIHIR ZAVERI Tags: Hardeman, Edwin Non-Hodgkin's Lymphoma Pesticides Defoliants and Herbicides Hazardous and Toxic Substances Suits and Litigation (Civil) Monsanto Company Bayer AG Source Type: news

Jury finds Monsanto's Roundup caused another man's cancer
It's the second verdict finding the active ingredient, glyphosate, led to non-Hodgkin's lymphoma in a California man (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2019 Category: Consumer Health News Source Type: news

FDA Busts J & amp;J and Sientra Over Breast Implant Compliance
FDA busted two manufacturers of silicone gel-filled breast implants this week for failure to comply with post-approval study requirements. The agency sent warning letters to Irvine, CA-based Mentor Worldwide, a unit of Johnson & Johnson, and to Santa Barbara, CA-based Sientra for deficiencies in each company's post-approval study for silicone breast implant approvals. Breast implants have been a source of contention between patient advocacy groups, industry, and FDA for decades. Implants were banned from the U.S. market from 1992 to 2006, and the devices have been the cause of an ove...
Source: MDDI - March 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Jury finds Bayer ’s Roundup as factor in cancer case
A federal jury in San Francisco ruled Tuesday that the weedkiller Roundup, a product developed by Monsanto that was acquired by Bayer, played a significant role in a man ’s cancer.  Edwin Hardeman, a California resident, used the weedkiller in his yard, and the jury found that the exposure to Roundup caused him to develop non-Hodgkin lymphoma, according to the Wall Street Journal. Now the case moves into the next phase for jurors to decide whether the Monsanto unit of Bayer is liable, which could… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 20, 2019 Category: American Health Authors: Vince Brennan Source Type: news